Despite the rapid and significant advancements in deep learning for Quantitative Structure-Activity Relationship (QSAR) models, the challenge of learning robust molecular representations that effectively generalize in real-world scenarios to novel compounds remains an elusive and unresolved task. This study examines how atom-level pretraining with quantum mechanics (QM) data can mitigate violations of assumptions regarding the distributional similarity between training and test data and therefore improve performance and generalization in downstream tasks. In the public dataset Therapeutics Data Commons (TDC), we show how pretraining on atom-level QM improves performance overall and makes the activation of the features distributes more Gaussian-like which results in a representation that is more robust to distribution shifts. To the best of our knowledge, this is the first time that hidden state molecular representations are analyzed to compare the effects of molecule-level and atom-level pretraining on QM data.
The versatility of multimodal deep learning holds tremendous promise for advancing scientific research and practical applications. As this field continues to evolve, the collective power of cross-modal analysis promises to drive transformative innovations, opening new frontiers in chemical understanding and drug discovery. Hence, we introduce Asymmetric Contrastive Multimodal Learning (ACML), a specifically designed approach to enhance molecular understanding and accelerate advancements in drug discovery. ACML harnesses the power of effective asymmetric contrastive learning to seamlessly transfer information from various chemical modalities to molecular graph representations. By combining pre-trained chemical unimodal encoders and a shallow-designed graph encoder with 5 layers, ACML facilitates the assimilation of coordinated chemical semantics from different modalities, leading to comprehensive representation learning with efficient training. We demonstrate the effectiveness of this framework through large-scale cross-modality retrieval and isomer discrimination tasks. Additionally, ACML enhances interpretability by revealing chemical semantics in graph presentations and bolsters the expressive power of graph neural networks, as evidenced by improved performance in molecular property prediction tasks from MoleculeNet and Therapeutics Data Commons (TDC). Ultimately, ACML exemplifies its potential to revolutionize molecular representational learning, offering deeper insights into the chemical semantics of diverse modalities and paving the way for groundbreaking advancements in chemical research and drug discovery.
While investigating methods to predict small molecule potencies, we found random forests or support vector machines paired with extended-connectivity fingerprints (ECFP) consistently outperformed recently developed methods. A detailed investigation into regression algorithms and molecular fingerprints revealed gradient-boosted decision trees, particularly CatBoost, in conjunction with a combination of ECFP, Avalon, and ErG fingerprints, as well as 200 molecular properties, to be most effective. Incorporating a graph neural network fingerprint further enhanced performance. We successfully validated our model across 22 Therapeutics Data Commons ADMET benchmarks. Our findings underscore the significance of richer molecular representations for accurate property prediction.
The absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties are important in drug discovery as they define efficacy and safety. In this work, we applied an ensemble of features, including fingerprints and descriptors, and a tree-based machine learning model, extreme gradient boosting, for accurate ADMET prediction. Our model performs well in the Therapeutics Data Commons ADMET benchmark group. For 22 tasks, our model is ranked first in 18 tasks and top 3 in 21 tasks. The trained machine learning models are integrated in ADMETboost, a web server that is publicly available at https://ai-druglab.smu.edu/admet.
Therapeutics machine learning is an emerging field with incredible opportunities for innovatiaon and impact. However, advancement in this field requires formulation of meaningful learning tasks and careful curation of datasets. Here, we introduce Therapeutics Data Commons (TDC), the first unifying platform to systematically access and evaluate machine learning across the entire range of therapeutics. To date, TDC includes 66 AI-ready datasets spread across 22 learning tasks and spanning the discovery and development of safe and effective medicines. TDC also provides an ecosystem of tools and community resources, including 33 data functions and types of meaningful data splits, 23 strategies for systematic model evaluation, 17 molecule generation oracles, and 29 public leaderboards. All resources are integrated and accessible via an open Python library. We carry out extensive experiments on selected datasets, demonstrating that even the strongest algorithms fall short of solving key therapeutics challenges, including real dataset distributional shifts, multi-scale modeling of heterogeneous data, and robust generalization to novel data points. We envision that TDC can facilitate algorithmic and scientific advances and considerably accelerate machine-learning model development, validation and transition into biomedical and clinical implementation. TDC is an open-science initiative available at https://tdcommons.ai.